Aura Biosciences(NASDAQ) AURA

Aura Biosciences creates precision therapies to treat cancer while saving healthy organ tissue. These treatments help patients with rare eye and bladder cancers avoid invasive surgery and vision loss. The company's lead drug uses light-activated molecules to kill tumors and trigger an immune response.

Precision Tools for Fighting Cancer

• Ocular Oncology: Developing treatments for early choroidal melanoma, a life-threatening eye cancer with no approved vision-sparing drugs.
• Urologic Oncology: Testing therapies for non-muscle-invasive bladder cancer, which affects roughly 80,000 people annually in the United States.
• VDC Platform: Using virus-like drug conjugates (VDCs) to deliver toxic payloads directly to tumor cells using light activation.

Strategic Partnerships and Milestones

• Licensed worldwide rights from the NIH for technology using virus-like particles to target and treat various solid tumors.
• Assumed a license and supply agreement with Rakuten Medical in April 2024 for specialized dye molecules used in light-activated therapy.
• Expanded a license agreement with Clearside Biomedical in March 2026 for microinjector technology that delivers drugs directly to the eye.
• Launched the global Phase 3 CoMpass trial to evaluate its lead candidate as a primary treatment for adult eye cancer patients.

Targeting Tumors Differently

Aura uses modified virus-like particles that bind only to specific receptors found on tumor cells to spare healthy tissue. This approach kills cancer cells directly while activating the body's immune system to provide long-term protection against the disease.

A Look at the Numbers

• Gross profit reached $600,000 in Q4 2025, up 306% from a loss of $291,000 in Q4 2024.
• Operating income was negative $27.2 million in Q4 2025, which narrowed by 2% from the prior year.
• Net loss reached $25.6 million in Q4 2025, showing a 1.1% improvement compared to Q4 2024.
• Free cash flow hit negative $20.6 million in Q4 2025, up 14.9% from the $24.3 million loss in Q4 2024.

The Road Ahead

Aura has evolved from an early-stage researcher into a clinical-stage developer of specialized cancer treatments. The company continues to advance its light-activated platform to address high unmet needs in ocular and urologic oncology.